Genetics & Genomics

Metastatic Prostate Cancer: Effects of Genetic Testing on Care

Laurie M. Connors

metastatic prostate cancer, genetic testing, Lynch syndrome, BRCA1/2
CJON 2019, 23(1), 32-35. DOI: 10.1188/19.CJON.32-35

The National Comprehensive Cancer Network now recommends BRCA1/2 genetic testing in men with metastatic prostate cancer. The purpose of this article is to provide a review of principles of genetic testing in prostate cancer and highlight the significance of clinical genetic testing of BRCA1/2 and other genes (CHEK2, HOXB13, PALB2), including Lynch syndrome genes (MLH1, MSH2, MSH6, and PMS2) in men with metastatic prostate cancer. The potential impact of genetic testing on systemic treatments and the significance of the pathogenic results for at-risk family members is discussed.


  • BRCA1/2 genetic testing is indicated for men with metastatic prostate cancer, regardless of age or family history.
  • Genetic testing results for BRCA1/2 and other cancer susceptibility genes affect treatment options and recommendations for cancer prevention and detection in men with metastatic prostate cancer.
  • Identification of a genetic mutation has implications for at-risk family members and provides opportunities for cancer screening and prevention.
Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.